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Introduction: Current asthma guidelines recommend step-down of inhaled corticosteroids
(ICS) to the minimum dose required for control of symptoms.
Aim: To determine if supervised step-down of (ICS) in the community has any effect on asth-
matic inflammation.
Methods: 119 Community based asthmatics underwent progressive step-down of therapy until
they became unstable or reached an (ICS) dose of 200 mg beclomethasone dipropionate (BDP)
or equivalent. Once unstable, participants stepped back up to the last stable dose of ICS.
Exhaled nitric oxide (NO) and mannitol challenge were performed at the start and end of
step-down. Asthma Quality of Life Questionnaire (AQLQ) and spirometry were recorded at each
step-down visit.
Results: The median (interquartile range) BDP equivalent dose was significantly higher pre vs.
post step-down: 400 mg (400e800) and 250 mg (200e400) per day respectively (P < 0.05). Exam-
ination of change in PD10 in individual patients revealed that 34% had an improvement (>þ1
dd), 47% had no change (1 dd), and 19% had a worsening (<1 dd). The geometric mean
fold ratio in NO for pre vs. post was 0.96 (95% CI 0.87 to 1.06, P Z 0.43). Mean (SEM) values
for FEV1 were 86.2% (1.51) vs. 84.5% (1.46) (P Z 0.04). There was a significant improvement
in AQLQ.
Conclusions: We have demonstrated that a significant reduction in ICS dose may be achieved in
a community setting without any worsening of airways inflammation or lung function, and withAllergy Research Group, Division of Medical Sciences, Ninewells Hospital & Medical School and Perth
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ICS Step-down does not increase inflammation 559an associated improvement quality of life in the majority of patients. This apparent disconnect
may reflect enhanced adherence due to supervision of step-down.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are the first line anti-inflam-
matory therapy in the treatment of asthma1,2 however
higher doses are associated with local and systemic adverse
effects3 Current asthma guidelines recommend stepping
down of steroid dose once asthma control has been ach-
ieved.1 There is a little evidence to suggest the best
method to step-down treatment, or to ensure the safety of
this approach. Hawkins and colleagues reduced the ICS
dose in a range of asthmatic patients by a mean of 25%
without a significant rise in asthma exacerbations or change
in measures of health status.4 They did not, however,
examine surrogates of inflammation or airway hyper-
responsiveness (AHR). It is recognised that symptoms
correlate poorly with underlying inflammation.5 Studies
have demonstrated that titrating ICS to suppress surrogates
of inflammation leads to reduced exacerbations and
decreased airways remodelling.6, 7 During the initial run-in
phase of an ongoing community based clinical trial, ICS
doses were stepped down to determine the lowest dose
required to achieve stability. During this phase inflamma-
tory surrogates including exhaled nitric oxide (NO) and AHR
to mannitol were measured, in additional to lung function
and quality of life. Mannitol was selected because it is
portable and easy to use in a community setting. In addi-
tion, AHR to mannitol has been shown to be a good
predictor of failure of ICS step-down.8Methods
Participants
119 Eligible patients were recruited from 35 general prac-
tices throughout Tayside. This paper presents data obtained
during the step-down phase of a large community based
study. Participants were required to be aged 16 years and
above, non smokers, have a diagnosis of persistent mild to
moderate asthma, be clinically stable, and currently treated
with 400 mg beclomethasone dipropionate (BDP) equiva-
lent. At point of entry into the study, patients were required
to demonstrate AHR to mannitol challenge in terms of a 10%
fall in FEV1 to a dose of mannitol of 635 mg or less. Exclusion
criteria were: oral steroid in the preceding three months;
aspirin intolerance; FEV1  50% predicted; pregnancy;
recurrent lower respiratory tract infections; and the pres-
ence of concomitant respiratory disease such as bronchiec-
tasis. Patients who failed to become unstable on 200 mg BDP
equivalent, or who were unable to step below 800 mg were
withdrawn, as these were entry criteria for the subsequent
study. The study was approved by the Tayside Committee on
Medical Ethics (CTA, MF8000/13398), and all participants
gave written informed consent.Protocol
Patients underwent systematic step-down of their medi-
cation with two weekly follow-up. At screening, patients
were issued with a peak expiratory flow (PEF) and symptom
diary card and asked to monitor their PEF for two weeks:
this served as their baseline for the study. Additional
asthma therapies (leukotriene receptor antagonists (LTRAs)
or theophyllines) were discontinued. Patients on combina-
tion inhalers were switched to an equivalent dose of
inhaled steroid only. The dose of inhaled steroid was then
halved every two weeks till patients were on 200 mg BDP
equivalent or became clinically unstable (see Fig. 1). Clin-
ical instability was defined as: diurnal variation in domi-
ciliary PEF  20%; deterioration in FEV1  20% from
baseline; mean use of inhaled reliever medication  0.5
puffs daily from baseline; an increase in symptom scores of
0.5 daily from baseline. (The asthma symptom score asks
for a number analogue of symptoms from 0 to 3, where: 0 is
symptom free; 1 is minimal symptoms; 2 is moderate
symptoms which may limit activity; 3 severe symptoms
which limit activity). Once unstable, participants stepped
back up to the last stable dose of ICS (this was designated
the ‘lowest dose required for stability’). Exhaled NO and
AHR were recorded at the start and end of the step-down,
while asthma quality of life questionnaires and spirometry
were measured throughout the step-down period.
Lung function
Lung function (FVC (forced vital capacity), FEV1 (forced
expiratory volume in 1 s)) was measured using a Micro
Medical SuperSpiro (Micro Medical Ltd, Rochester, UK)
spirometer according to the American Thoracic Society
guidelines.9 The highest of 3 values for FEV1, repeatable
within 5%, was recorded and the percentage of percent
predicted was calculated.
Mannitol challenge
Mannitol bronchial challenge was performed by adminis-
tering mannitol gelatine capsules (Osmohale Pharmaxis
Ltd, Sydney, Australia), inhaled from a dry powder device
(Osmohaler, Pharmaxis Ltd. French’s Forest, NSW,
Australia) as previously described.10 FEV1 was measured 60
s after delivery of each dose (5, 10, 20, 40, 80, 160, 160,
160 mg). The test continued until the FEV1 had fallen 10% or
the maximal cumulative dose of 635 mg had been admin-
istered. The provoking dose of mannitol to cause a 10% fall
in FEV1 (PD10) was calculated by log linear interpolation.
Nitric oxide measurement
All participants underwent measurement of exhaled NO
using a portable MINO (NIOX MINO Airway Inflammation
Figure 1 Step-down procedure.
560 K.L. Clearie et al.Monitor; Aerocrine AB, Solna, Sweden). Exhaled nitric oxide
was measured during a sustained plateau of at least 8 s with
a mouth flow rate of 50 ml/s and a pressure of 10 cm H2O
following a tidal breath. The arithmetic mean was derived
according to the current European Respiratory Society/
American Thoracic Society recommendations.
Mini juniper quality of life questionnaires (Mini-
AQLQ)
At each study visit each patient completed the Juniper
mini-AQLQ.11
Statistical analysis
SPSS version 15 (SPSS Inc, Chicago, Illinois) was used to
perform the statistical analysis. Normality of data was
assessed using the KolmogoroveSmirnov; non-Gaussian data
were log transformed prior to analysis. Gaussian data wereassessed using paired Student’s t-tests. ICS dose pre and
post step-down was analysed using Wilcoxon Signed Rank
Tests. A probability value of less than 0.05 (two tailed) was
considered significant.Results
Demographics
One hundred and fifty patients entered the step-down
phase of the clinical trial. One hundred and nineteen (49%
female, 52% male) of these were randomised and entered
the subsequent clinical trial. Thirty-one patients withdrew
during the step-down phase: 1 failed to become unstable
when cut back to 200 mg ICS; 2 became unstable on800 mg
ICS; 3 were unable to discontinue long acting beta agonist
therapy; 2 were withdrawn due to failure to comply with
the protocol; 6 withdrew due to personal reasons; and 17
ICS Step-down does not increase inflammation 561were lost to follow-up. The mean (SEM) age of participants
who dropped out was 57 years (2) compared with 52 years
(1) in those who completed step-down. Dropouts also had
a significantly higher mannitol PD10: 184.5 mg (95% CI
113.5e299.8) compared with 100 mg (95% CI 76.2e131.2), P
Z 0.036. Other baseline characteristics did not differ
significantly between the two groups (Table 1).Figure 2 Median change in ICS dose (mg) pre and post step-
down.Withdrawal of medication
23 Participants were taking additional third line asthma
therapy (long-acting b2-agonists (n Z 21), theophylines (n
Z 1) or leukotriene receptor antagonists (n Z 1)) at the
start of the step-down. Only four participants did not
tolerate withdrawal of their third line therapy; one with-
drew voluntarily. In patients who completed step-down,
the median (interquartile range) dose of BDP or equivalent
was 400 mg (400e800) at baseline, compared with 250 mg
(200e400) post step-down, giving a median reduction of
150 mg (P < 0.0001) (Fig. 2). Subjects underwent an average
of 1.49 (0.07) step downs prior to either becoming unstable
or reaching 200 mg BDP equivalent.Surrogates of inflammation
The geometric mean (95% CI) mannitol PD10 was 100.0
(76.2e131.2) at baseline; and 137.2 (104.5e180.1) post
step-down. This represents a 0.46 doubling dose difference
for pre vs. post step-down (95% CI 0.02e0.89), P Z 0.04.
The geometric mean response-dose-ratio (%fall in FEV1/
cumulative dose of mannitol given) was 1.73% fall/mg
(1.71e1.75) at baseline and 1.95% fall/mg (1.93e1.96) post
step-down, pZ 0.73. The geometric mean fold ratio for pre
vs. post in exhaled NO was 0.96 (0.87e1.06), P Z 0.43.
Lung function
Mean (SEM) baseline spirometry values were: FEV1 of 86.2%
(1.5), FVC 91.6% (1.4), PEF 90.2% (1.7). FEV1 post step-
down was 84.5% (1.5), P < 0.05. FVC and PEF showed noTable 1 Completed vs. drop-outs.
Variable Completed
BDP equivalent ICS dose (mcg/day)a 400 (400e800)
Mannitol PD10 (mg)
b 99.99 (76.2e13
Exhaled nitric oxide (ppb)b 26.79 (22.1e32
Spirometryc
FEV1% predicted 86.16 (1.512)
FVC % predicted 91.56 (1.376)
PEF % predicted 90.20 (1.695)
Age 52.00
Sex (F:M) 48.7%:51.3%
Abbreviations: ICS, inhaled corticosteroids; FEV1, forced expiratory vo
rate; PD10, provocative dose of mannitol causing a 10% decrease in F
Data presented as arithmetic mean (SEM) unless otherwise indicated.
a Expressed as median (interquartile range).
b Shown as geometric mean (95% CI).
c Expressed as percentage of that predicted by age, sex, and heighsignificant change post step-down (91.5% (1.4), and 90.0%
(1.6), P Z 0.87).
AQLQ
The mean (SEM) AQLQ composite scores pre and post step-
down were 5.44 (0.10) vs. 5.83 (0.09) respectively, repre-
senting a mean improvement of 0.39 (95% CI 0.26 to 0.52), P
< 0.001. Individual domains also showed statistically
significant improvements (Tables 2 and 3).
Discussion
The present study demonstrates that supervised step-down
of ICS in a community setting can be achieved without any
worsening of airways inflammation, as measured by exhaled
NO and mannitol challenge. This is in agreement with work
carried out by Leuppi et al., who determined that the
majority of patients could undergo a halving of their ICS dose
without exacerbation.8 We hypothesize that this may be due
to improved adherence with supervised treatment duringDrop-outs P-Value
800 (400e1000) 0.055
1.2) 184.47 (113.5e299.8) 0.036
.5) 17.83 (9.9e32.0) 0.144
90.13 (3.396) 0.244
95.13 (3.215) 0.254
91.61 (3.910) 0.713
57.83 0.049
62.1%:37.9%
lume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow
EV1.
t, mean (SEM).
Table 2 Pre vs. post step down parameters.
Variable Baseline Post step-down P value
BDP equivalent ICS dose (mcg/day)a 400 (400e800) 250 (200e400) <0.0001
Mannitol PD10 (mg)
b 99.99 (76.2e131.2) 137.19 (104.5e180.1) 0.04
Exhaled nitric oxide (ppb)b 26.79 (22.1e32.5) 27.93 (23.4e33.4) 0.43
Spirometryc
FEV1% predicted 86.16 (1.51) 84.46 (1.46) 0.04
FVC % predicted 91.56 (1.38) 91.52 (1.44) 0.97
PEF % predicted 90.20 (1.70) 90.02 (1.56) 0.87
AQLQ
Symptoms 5.22 (0.11) 5.65 (0.10) <0.0001
Activity limitations 5.18 (0.13) 5.68 (0.11) <0.0001
Emotional function 5.44 (0.11) 5.79 (0.10) <0.0001
Total stimuli 5.40 (0.11) 5.82 (0.10) <0.0001
Total score 5.44 (0.10) 5.83 (0.10) <0.0001
Abbreviations: ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow
rate; PD10, provocative dose of mannitol causing a 10% decrease in FEV1.
Data presented as arithmetic mean (SEM) unless otherwise indicated. Baseline values are shown after washout before each randomised
treatment period.
Step-down measurements were taken 2 weeks after reduction in steroid dose.
a Expressed as median (interquartile range).
b Shown as geometric mean (95% CI).
c Expressed as percentage of that predicted by age, sex, and height, mean (SEM).
562 K.L. Clearie et al.step-down. Whilst a significant reduction in ICS could also be
achieved if patients had initially been over treated, there
should have been a commensurate increase in airways
inflammation on withdrawal of treatment, as has been
reported elsewhere.12 In the absence of such a change we
feel that enhanced adherence is the logical conclusion.
Adherence with asthma medications, particularly ICS, is
known to be poor.13 Patient-reported adherence rates are as
low as 38%,14,15 and actual drug use is often even lower. Rand
et al. compared patient-reported adherence to change in
canister weight and demonstrated that although 73% of
participants reported using their ICS three times daily, this
was only confirmed in 15% by canister weight.15
The commonest reasons to explain non-adherence
include: patients’ perception of their disease; such that
they only take ICS when they become unwell as opposed to
using it as ‘preventer’ therapy14; and concerns over
potential side effects.13 There is evidence to suggest that
regular disease monitoring addresses these issues and leads
to benefits such as improved inhaler technique and adher-
ence.16, 17 In this regard, patients in the present study were
reviewed fortnightly and may have additionally benefited
from the positive reinforcement of regular spirometry, peak
flow and symptom monitoring. Whilst this high level ofTable 3 Juniper mini-AQLQ.
Mean pre Mean post
Total score 5.44 5.83
Symptoms 5.22 5.65
Activity limitations 5.18 5.68
Emotional function 5.44 5.79
Environmental stimuli 5.40 5.82supervision is too intensive to be reproduced in primary
care, it suggests that the widespread practice of annual
review may be too infrequent to adequately educate and
support our asthmatic population.
Control of airways inflammation is of critical importance
in asthma, as if left uncontrolled long-term it can lead to
airway remodelling, even in asymptomatic patients.18
Furthermore, studies in which asthma therapy was
titrated to achieve suppression of surrogates of inflamma-
tion demonstrate that exacerbation rates can be reduced
by up to five-fold, when compared with treatment guided
by symptoms and lung function alone.6,7 To address this,
the present study utilised bronchial challenge with
mannitol and exhaled NO as suitable surrogates of asth-
matic inflammation. Bronchial challenge tests are tradi-
tionally used to diagnose the presence of AHR, and to
monitor response to treatment.19 A.HR is a key feature of
persistent asthma, which is considered to correlate well
with underlying airways inflammation.6 All participants in
this study were required to exhibit AHR to mannitol as one
of the inclusion criteria. Hence, we consider this makes an
alternative diagnosis to asthma such as eosinophilic bron-
chitis unlikely. Nonetheless, we appreciate that AHR may
vary over time, often increasing during exacerbations andDifference in means P value 95% CI
0.39 <0.0001 0.26 to 0.52
0.42 <0.0001 0.26 to 0.59
0.49 <0.0001 0.33 to 0.66
0.36 <0.0001 0.20 to 0.51
0.42 <0.0001 0.28 to 0.56
ICS Step-down does not increase inflammation 563decreasing during treatment with anti-inflammatory
therapy.20
Mannitol challenge is a relatively novel indirect bron-
chial challenge test, which is known to be reproducible,
and to correlate well with other surrogate markers of
airways inflammation.10,21 Unlike other challenge tests, it is
portable, simple, and quick to perform, and therefore
ideally suited for use in primary care. Moreover, mannitol is
an indirect stimulus, which induces AHR by osmotically
stimulating inflammatory cells to release mediators which
constrict airway smooth muscle. Fardon et al. showed that
PD10 correlates well with PD15, allowing an abbreviated
challenge to be utilised without loss of sensitivity, whilst
exposing the subject to less provocation agent.22 The
overall mean improvement observed in mannitol challenge
(0.46 doubling dose shift in mannitol PD10) was statistically
significant, but would not be considered clinically signifi-
cant. Examination of change in PD10 in individual patients,
as depicted in Fig. 3, is more revealing than the magnitude
of the overall mean shift for the group as a whole. A change
in mannitol PD10 of 1 doubling dose in a given patient is
within the limits of intra-individual biological variability.
Using these criteria we identified 34% of patients who had
an improvement in PD10 (i.e. a change >þ1 doubling dose),
47% who had no change (i.e. a change within 1 doubling
dose), and 19% who had a worsening (i.e. change <1Figure 3 Doubling dose shift (i.e. post step-down PD10 minus
pre step-down PD10) in mannitol for each individual patient.
The intra-individual biological variability of mannitol challenge
is 1 dd, so individuals lying between þ1 and 1 (depicted by
interrupted line) can be assumed to show ‘no change’ in
mannitol challenge post step-down (47%). Individuals with >þ1
dd demonstrated an improvement in mannitol challenge (34%).
Those with a <1 dd shift demonstrated a worsening in
mannitol challenge (19%).doubling dose) when comparing pre vs. post step-down
(Fig. 3). In other words it was evident that the majority of
patients (i.e. 81%) either had no change in AHR or
improved. A minority of patients showed a worsening of
AHR, which would be expected if subjects were initially
adherent with treatment. A rate of 19% is consistent with
adherence rates reported in previous studies.15 A compar-
ison of the baseline and post step-down characteristics of
these three groups revealed no significant differences in
terms of spirometry, NO or ICS dose, suggesting that in the
majority of patients, airway inflammation was well
controlled (Table 4). Analysis of mannitol PD10 showed that
those who improved post step-down had significantly
greater bronchial hyper-reactivity at baseline than the
other two groups. Those who worsened post step-down had
significantly more bronchial hyper-reactivity at the end of
step-down. This correlates well with data obtained by
Leuppi et al. who determined that developing AHR to
mannitol during dose reduction was a good predictor of
step-down failure.8
Exhaled NO is an established surrogate of airways
inflammation in asthma23 and correlates closely to
sputum eosinophil counts24,25 and mucosal eosinophilic
markers.26,27 When used on its own as an inflammatory
surrogate to titrate ICS, the results have been disap-
pointing,28 indeed, a recent Cochrane review has deter-
mined that exhaled nitric oxide cannot be recommended
for tailoring the dose of inhaled corticosteroids in clinical
practice.29 However, its rapid response to changes in
inflammatory status30 and acute sensitivity to ICS makes it
helpful when used in conjunction with other measures. It
has been used as an early predictor of under-treatment
(predicting exacerbation with FENO and dose reduction).
12
In this regard our cohort showed no net change in NO
during step-down. If the biological variability of NO is
assumed to be <30%31: 64% of subjects demonstrated no
significant increase in NO (Fig. 4), These results correlate
well with those of Leuppi et al. who found no significant
increase in NO during dose reduction or exacerbation. We
know from previous studies that 200 mg BDP is sufficient to
suppress NO, even in the presence of persisting AHR, which
may explain its lack of response in these circumstances.20
However, when this observation is taken in conjunction
with mannitol AHR, we believe it offers good evidence that
airway inflammation was well controlled in this study,
despite the relatively rapid rate at which ICS was reduced.
Larger studies with a longer duration of follow-up are
required to determine whether these improvements are
maintained long-term.
Despite evidence to support the use of inflammatory
markers in asthmatic assessment, current clinical practice
dictates that ICS should be adjusted according to patient-
reported symptoms and spirometry.1 In this respect, we
observed a statistically significant improvement in quality
of life scores, despite the reduction in ICS dose. There were
no clinically significant changes in spirometry.
Treatment of asthmatic patients in primary care has been
driven by results obtained from randomised controlled trials,
during which treatment compliance is reinforced. These
therefore, do not reflect a real life scenario. The current
paper highlights the potential pit falls of extrapolating data
to a primary care setting where compliance rates may be
Table 4 Baseline and post step down data vs. doubling dose shift post step down.
>þ1 Doubling dose change
“Improvement” (n Z 40)
1 Doubling dose change
“No change” (n Z 56)
<1 Doubling dose change
“Worsening” (n Z 23)
Pre Post Pre Post Pre Post
Mannitol PD10
(mg)a
36.7
(17.975.1)
284.4
(149.6540.6)
115.6
(73.7181.3)
112.3
(71.0117.7)
211.1
(33.0600.1)
26.0
(4.1166.9)
Exhaled Nitric
oxide (ppb)
24.6
(16.037.8)
26.5
(19.037.0)
27.0
(20.735.4)
28.4
(22.136.5)
14.4
(3.461.1)
19.9
(4.490.6)
Spirometry
FEV1% predicted 86.1 (4.8) 85.1 (5.1) 85.6 (2.6) 84.7 (2.7) 87.2 (8.6) 89.2 (10.1)
FVC % predicted 89.6 (3.5) 88.8 (4.4) 94.0 (2.7) 92.8 (2.8) 89.4 (9.2) 87.2 (8.2)
PEF % predicted 90.9 (4.7) 89.4 (4.4) 87.3 (2.7) 87.3 (2.8) 97.0 (9.6) 104.0 (6.5)
BDP equivalent
ICS dose
(mcg/day)
400
(400800)
200
(200400)
400
(400800)
200
(200400)
550
(4001000)
400
(212475)
Abbreviations: ICS, inhaled corticosteroids; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow
rate; PD10, provocative dose of mannitol causing a 10% decrease in FEV1.
Data presented as arithmetic mean (SEM) unless otherwise indicated. Baseline values are shown after washout before each randomised
treatment period. Post step down measurements were made 2 weeks after the final dose reduction.
a Significant difference (P < 0.01) between all three groups (except for pre step down dose between ‘no change’ and ‘worsening’).
564 K.L. Clearie et al.poor. Perhaps there is a need for the development of more
effective strategies which support asthmatics to use estab-
lished therapies correctly rather than continue a culture of
escalating therapy, without frequent review and step-down
if appropriate. Improvement of asthma care in the commu-
nity may require an approach that includes more effectiveFigure 4 Change in exhaled nitric oxide (i.e. post step-
downepre step-down) for each individual. The biological
variability for nitric oxide lies within 30%, so individuals lying
within þ30% and 30% (depicted by interrupted line) can be
assumed to show ‘no change’ in NO post step-down (43%).
Individuals with >þ30% change can be assumed to show a rise
in NO (worsening inflammation) (36%). Those with a <30%
change demonstrated a decrease in NO (improvement in
inflammation) (21%).supervision and targeted assessment to enhance adherence
and reduce airways inflammation.
In conclusion we have demonstrated that achieving
a significant reduction in ICS dose is possible, without any
deterioration in surrogate markers of inflammation in the
majority of patients, and with an associated improvement
in quality of life. This apparently disconnect between
reduction in anti-inflammatory therapy and measured
inflammation may reflect enhanced adherence through
frequent supervision.
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